Abstract
Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib
The prevalence of Anaplastic lymphoma kinase(ALK) rearrangement in NSCLC is about 7-10%. Currently, there are several ALK inhibitors available in treating this group of patients. Brain metastases occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with ALK inhibitor, CNS progression occurs in up to 70% of patients. Patients with brain metastases from ALK-positive NSCLC have a distinct natural history compared with patients with wild-type NSCLC. This article describes the rapid flare of brain metastases in ALK-positive non-small cell lung cancer after stopping Crizotinib.
Author(s):
Juengsamarn J, Sirachainan E and Reungwetwattana T
Abstract | Full-Text | PDF
Share this
30+ Million Readerbase
Abstracted/Indexed in
- Google Scholar
- China National Knowledge Infrastructure (CNKI)
- CiteFactor
- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Secret Search Engine Labs
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences